00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
16:41 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

AZ's anifrolumab misses in Phase III for lupus

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said anifrolumab (formerly MEDI-546) missed the primary endpoint in the Phase III TULIP 1 trial to treat systemic lupus erythematosus (SLE). Compared with placebo, anifrolumab failed...
18:15 , Aug 31, 2018 |  BC Extra  |  Clinical News

AZ's anifrolumab misses in Phase III for lupus

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said anifrolumab (formerly MEDI-546) missed the primary endpoint in the Phase III TULIP 1 trial to treat systemic lupus erythematosus (SLE). Compared with placebo, anifrolumab failed...
17:21 , Mar 2, 2018 |  BC Week In Review  |  Company News

MedImmune spins out autoimmune play Viela

The MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN) is spinning out six compounds into severe autoimmune disease play Viela Bio Inc. (Gaithersburg, Md.). Bing Yao, who is head of MedImmune’s Respiratory, Inflammation & Autoimmunity...
07:40 , Feb 28, 2018 |  BC Extra  |  Company News

MedImmune spins out autoimmune play Viela

MedImmune LLC is spinning out six compounds into severe autoimmune disease play Viela Bio Inc. (Gaithersburg, Md.). Bing Yao, who is head of the AstraZeneca plc (LSE:AZN; NYSE:AZN) subsidiary’s Respiratory, Inflammation & Autoimmunity (RIA) Innovative...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

Anifrolumab: Phase II data

A double-blind, international Phase II trial in 305 patients with seropositive moderate to severe SLE showed that 300 mg IV anifrolumab every 4 weeks met the primary endpoint of a greater proportion of patients achieving...
08:00 , Nov 16, 2015 |  BioCentury  |  Product Development

On SLE's trail

AstraZeneca plc's MedImmune LLC unit is following a clinical development trail for lupus candidate anifrolumab first blazed by Benlysta belimumab. The company hopes that its track record of successful mid-stage trials in the indication have...
02:25 , Nov 11, 2015 |  BC Extra  |  Clinical News

AZ reports Phase II SLE data

The MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) said the lower of two doses of anifrolumab ( MEDI-546 ) showed a statistically significant improvement on the primary endpoint in a Phase II trial to...
07:00 , May 19, 2014 |  BC Week In Review  |  Clinical News

Sifalimumab: Phase IIb data

AstraZeneca's MedImmune LLC unit reported top-line data from a double-blind, international Phase IIb trial in 431 patients with moderate to severe active SLE showing that 200, 600 and 1,200 mg doses of IV sifalimumab given...
07:00 , Apr 8, 2013 |  BioCentury  |  Strategy

AstraZeneca's reset

After spending at least $7 billion for late-stage assets in 2012, AstraZeneca plc believes it now has sufficient value in its Phase II/III pipeline to restore long-term growth. The attention of business development is now...